Avalo Therapeutics, Inc. Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -58.12. In total, the insiders bought 5 414 625 and sold 5 291 542 AVTX shares in the last 100 trades.

Insider Power

(Last 100 transactions)
-58.12
Buy 5 414 625 Shares
Sell 5 291 542 Shares

Historical Insider Trades

Date Type Action Person Amount
Jun 24, 2024 Stock Option (Right to Buy) Buy Varki Paul 150 000
Jun 24, 2024 Buy Varki Paul 0
Mar 28, 2024 Buy Truex Samantha 0
Mar 28, 2024 Buy Kantoff Aaron 0
Mar 27, 2024 Buy Goldman Jonathan 0
Dec 20, 2023 Stock Option (Right to Buy) Buy Persson Magnus 3 334
Dec 20, 2023 Stock Option (Right to Buy) Buy Almenoff June Sherie 3 334
Dec 20, 2023 Stock Option (Right to Buy) Buy Kaplan Gilla 3 334
Dec 20, 2023 Stock Option (Right to Buy) Buy Chan Mitchell 3 334
Jun 30, 2023 Stock Option (Right to Buy) Buy Persson Magnus 28 308
Jun 30, 2023 Stock Option (Right to Buy) Buy Almenoff June Sherie 4 575
Jun 27, 2023 Common Stock Sell Armistice Capital, Llc 937 404
Jun 26, 2023 Common Stock Sell Armistice Capital, Llc 2 746 138
Jun 26, 2023 Common Stock Sell Caissa Capital Management Ltd. 1 425 700
Jun 26, 2023 Common Stock Sell Caissa Capital Management Ltd. 182 300
Jun 20, 2023 Common Stock Buy Caissa Capital Management Ltd. 2 000
Jun 16, 2023 Common Stock Buy Caissa Capital Management Ltd. 3 000
Jun 15, 2023 Common Stock Buy Caissa Capital Management Ltd. 3 160
Jun 14, 2023 Common Stock Buy Caissa Capital Management Ltd. 6 000
Jun 13, 2023 Common Stock Buy Caissa Capital Management Ltd. 8 750
Jun 12, 2023 Common Stock Buy Caissa Capital Management Ltd. 2 149
Jun 09, 2023 Common Stock Buy Sullivan Christopher Ryan 511
Jun 09, 2023 Common Stock Buy Neil Garry Arthur 4 000
Jun 09, 2023 Common Stock Buy Caissa Capital Management Ltd. 5 044
Jun 08, 2023 Common Stock Buy Caissa Capital Management Ltd. 6 398
Click to get the best stock tips daily for free!

About Avalo Therapeutics, Inc.

Avalo Therapeutics. Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe... AVTX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT